Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

• Status: Completed
• Trial end date: 2011-10-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Allergan
• Treatments: Brimonidine Tartrate; Temazepam

Criteria

Inclusion Criteria:

• Plan on having a pars plana vitrectomy for repair of a posterior segment condition (eg, epiretinal membrane, macular hole, vitreomacular traction)

• Visual acuity in the non-study eye better than 20/200

Exclusion Criteria:

• History of pars plana vitrectomy or retinal detachment surgery in the study eye

• Surgery or laser treatment in the study eye within 3 months

• Use of brimonidine, apraclonidine or other topical alpha-2-agonist in either eye within 2 weeks

• Intraocular infection or inflammation